Go Pro
→ SpaceX IPO hides a much bigger story (From Weiss Ratings) (Ad)tc pixel Free TLSA Stock Alerts

Tiziana Life Sciences (TLSA) Competitors

Tiziana Life Sciences logo
$1.28 +0.05 (+4.07%)
Closing price 06/30/2026 04:00 PM Eastern
Extended Trading
$1.30 +0.02 (+1.88%)
As of 06/30/2026 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TLSA vs. DNA, TECX, AVTE, MNPR, and CTMX

Should you buy Tiziana Life Sciences stock or one of its competitors? MarketBeat compares Tiziana Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tiziana Life Sciences include Ginkgo Bioworks (DNA), Tectonic Therapeutic (TECX), Aerovate Therapeutics (AVTE), Monopar Therapeutics (MNPR), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry.

How does Tiziana Life Sciences compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Tiziana Life Sciences has lower revenue, but higher earnings than Ginkgo Bioworks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ginkgo Bioworks$170.15M3.81-$312.76M-$5.36N/A
Tiziana Life SciencesN/AN/A-$18.43MN/AN/A

In the previous week, Tiziana Life Sciences had 2 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 1 mentions for Ginkgo Bioworks. Tiziana Life Sciences' average media sentiment score of 0.63 beat Ginkgo Bioworks' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ginkgo Bioworks
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tiziana Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Tiziana Life Sciences has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Tiziana Life Sciences' return on equity of 0.00% beat Ginkgo Bioworks' return on equity.

Company Net Margins Return on Equity Return on Assets
Ginkgo Bioworks-215.41% -56.08% -26.06%
Tiziana Life Sciences N/A N/A N/A

Ginkgo Bioworks currently has a consensus target price of $8.50, suggesting a potential downside of 14.46%. Given Ginkgo Bioworks' stronger consensus rating and higher probable upside, equities research analysts clearly believe Ginkgo Bioworks is more favorable than Tiziana Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ginkgo Bioworks
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
Tiziana Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Ginkgo Bioworks has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

Summary

Tiziana Life Sciences beats Ginkgo Bioworks on 7 of the 13 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Tectonic Therapeutic has a beta of 3.19, indicating that its stock price is 219% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

In the previous week, Tiziana Life Sciences had 2 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 1 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.87 beat Tiziana Life Sciences' score of 0.63 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company Overall Sentiment
Tectonic Therapeutic Very Positive
Tiziana Life Sciences Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tectonic TherapeuticN/AN/A-$74.15M-$4.46N/A
Tiziana Life SciencesN/AN/A-$18.43MN/AN/A

Tiziana Life Sciences' return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company Net Margins Return on Equity Return on Assets
Tectonic TherapeuticN/A -32.33% -30.92%
Tiziana Life Sciences N/A N/A N/A

Tectonic Therapeutic currently has a consensus price target of $79.40, suggesting a potential upside of 130.95%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, equities analysts clearly believe Tectonic Therapeutic is more favorable than Tiziana Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tectonic Therapeutic
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00
Tiziana Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

62.6% of Tectonic Therapeutic shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Tectonic Therapeutic beats Tiziana Life Sciences on 7 of the 12 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Aerovate Therapeutics?

Tiziana Life Sciences (NASDAQ:TLSA) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

In the previous week, Tiziana Life Sciences had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 0 mentions for Aerovate Therapeutics. Tiziana Life Sciences' average media sentiment score of 0.63 beat Aerovate Therapeutics' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Tiziana Life Sciences Positive
Aerovate Therapeutics Neutral

Tiziana Life Sciences' return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Aerovate Therapeutics N/A -90.19%-77.47%

Tiziana Life Sciences has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life SciencesN/AN/A-$18.43MN/AN/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tiziana Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Tiziana Life Sciences beats Aerovate Therapeutics on 6 of the 7 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Monopar Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Monopar Therapeutics presently has a consensus target price of $108.75, indicating a potential upside of 17.45%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Monopar Therapeutics is more favorable than Tiziana Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monopar Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00
Tiziana Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

1.8% of Monopar Therapeutics shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Monopar Therapeutics had 3 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 6 mentions for Monopar Therapeutics and 3 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.63 beat Monopar Therapeutics' score of 0.50 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Monopar Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tiziana Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monopar TherapeuticsN/AN/A-$13.72M-$1.90N/A
Tiziana Life SciencesN/AN/A-$18.43MN/AN/A

Tiziana Life Sciences' return on equity of 0.00% beat Monopar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Monopar TherapeuticsN/A -12.84% -12.57%
Tiziana Life Sciences N/A N/A N/A

Summary

Monopar Therapeutics beats Tiziana Life Sciences on 8 of the 12 factors compared between the two stocks.

How does Tiziana Life Sciences compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

CytomX Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

In the previous week, Tiziana Life Sciences had 2 more articles in the media than CytomX Therapeutics. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 1 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.89 beat Tiziana Life Sciences' score of 0.63 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
CytomX Therapeutics Very Positive
Tiziana Life Sciences Positive

CytomX Therapeutics has higher revenue and earnings than Tiziana Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytomX Therapeutics$76.20M8.38-$17.37M-$0.41N/A
Tiziana Life SciencesN/AN/A-$18.43MN/AN/A

CytomX Therapeutics currently has a consensus price target of $12.10, indicating a potential upside of 222.67%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe CytomX Therapeutics is more favorable than Tiziana Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytomX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91
Tiziana Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Tiziana Life Sciences has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. Tiziana Life Sciences' return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CytomX Therapeutics-166.40% -36.61% -28.02%
Tiziana Life Sciences N/A N/A N/A

67.8% of CytomX Therapeutics shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

CytomX Therapeutics beats Tiziana Life Sciences on 9 of the 14 factors compared between the two stocks.

Get Tiziana Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLSA vs. The Competition

Export
MetricTiziana Life SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$156.53M$3.66B$7.07B$12.45B
Dividend YieldN/A2.20%2.66%6.16%
P/E RatioN/A20.9027.2524.87
Price / SalesN/A341.80543.53102.84
Price / CashN/A143.7748.5358.59
Price / BookN/A8.7510.936.54
Net Income-$18.43M$23.81M$3.57B$336.70M
7 Day Performance14.29%3.60%2.31%2.88%
1 Month Performance-8.57%3.72%1.39%0.64%
1 Year Performance-17.42%68.80%36.73%31.34%

Tiziana Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TLSA
Tiziana Life Sciences
0.5005 of 5 stars		$1.28
+4.1%		N/A-19.0%$156.53MN/AN/A8
DNA
Ginkgo Bioworks
0.2826 of 5 stars		$8.87
-1.9%		$8.50
-4.2%		-12.0%$579.39M$170.15MN/A640
TECX
Tectonic Therapeutic
3.4062 of 5 stars		$30.46
+0.4%		$79.40
+160.7%		+73.0%$574.78MN/AN/A120
AVTE
Aerovate Therapeutics
N/A$19.45
+15.6%		N/A+140.6%$563.76MN/AN/A20
MNPR
Monopar Therapeutics
1.9041 of 5 stars		$81.98
+19.4%		$107.91
+31.6%		+158.8%$549.27MN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TLSA) was last updated on 7/1/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel